Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 388

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial

Open access
Shah, Anoop S V, Anand, Atul, Strachan, Fiona E, Ferry, Amy V, Lee, Kuan Ken, Chapman, Andrew R, Sandeman, Dennis, Stables, Catherine L, Adamson, Philip D, Andrews, Jack P M, Anwar, Mohamed S, Hung, John, Moss, Alistair J, O'Brien, Rachel, Berry, Colin, Findlay, Iain, Walker, Simon, Cruickshank, Anne, Reid, Alan, Gray, Alasdair, Collinson, Paul O, Apple, Fred S, McAllister, David A, Maguire, Donogh, Fox, Keith A A, Newby, David E, Tuck, Christopher, Harkess, Ronald, Parker, Richard A, Keerie, Catriona, Weir, Christopher J, Mills, Nicholas L, Marshall, Lucy, Stewart, Stacey D, Fujisawa, Takeshi, Vallejos, Catalina A, Tsanas, Athanasios, Hautvast, Mischa, McPherson, Jean, McKinlay, Lynn, Malo, Jonathan, Fischbacher, Colin M, Croal, Bernard L, Leslie, Stephen J, Walker, Allan, Wackett, Tony, Armstrong, Roma, Stirling, Laura, MacDonald, Claire, Sadat, Imran, Finlay, Frank, Charles, Heather, Linksted, Pamela, Young, Stephen, Alexander, Bill, Duncan, Chris·2018·The Lancet

Abstract

BACKGROUND: High-sensitivity cardiac troponin assays permit use of lower thresholds for the diagnosis of myocardial infarction, but whether this improves clinical outcomes is unknown. We aimed to determine whether the introduction of a high-sensitivity cardiac troponin I (hs-cTnI) assay with a sex-specific 99th centile diagnostic threshold would reduce subsequent myocardial infarction or cardiovascular death in patients with suspected acute coronary syndrome. METHODS: In this stepped-wedge, cluster-randomised controlled trial across ten secondary or tertiary care hospitals in Scotland, we evaluated the implementation of an hs-cTnI assay in consecutive patients who had been admitted to the hospitals' emergency departments with suspected acute coronary syndrome. Patients were eligible for inclusion if they presented with suspected acute coronary syndrome and had paired cardiac troponin measurements from the standard care and trial assays. During a validation phase of 6-12 months, results from the hs-cTnI assay were concealed from the attending clinician, and a contemporary cardiac troponin I (cTnI) assay was used to guide care. Hospitals were randomly allocated to early (n=5 hospitals) or late (n=5 hospitals) implementation, in which the high-sensitivity assay and sex-specific 99th centile diagnostic threshold was introduced immediately after the 6-month validation phase or was deferred for a further 6 months. Patients reclassified by the high-sensitivity assay were defined as those with an increased hs-cTnI concentration in whom cTnI concentrations were below the diagnostic threshold on the contemporary assay. The primary outcome was subsequent myocardial infarction or death from cardiovascular causes at 1 year after initial presentation. Outcomes were compared in patients reclassified by the high-sensitivity assay before and after its implementation by use of an adjusted generalised linear mixed model. This trial is registered with ClinicalTrials.gov, number NCT01852123. FINDINGS: Between June 10, 2013, and March 3, 2016, we enrolled 48 282 consecutive patients (61 [SD 17] years, 47% women) of whom 10 360 (21%) patients had cTnI concentrations greater than those of the 99th centile of the normal range of values, who were identified by the contemporary assay or the high-sensitivity assay. The high-sensitivity assay reclassified 1771 (17%) of 10 360 patients with myocardial injury or infarction who were not identified by the contemporary assay. In those reclassified, subsequent myocardial infarction or cardiovascular death within 1 year occurred in 105 (15%) of 720 patients in the validation phase and 131 (12%) of 1051 patients in the implementation phase (adjusted odds ratio for implementation vs validation phase 1·10, 95% CI 0·75 to 1·61; p=0·620). INTERPRETATION: Use of a high-sensitivity assay prompted reclassification of 1771 (17%) of 10 360 patients with myocardial injury or infarction, but was not associated with a lower subsequent incidence of myocardial infarction or cardiovascular death at 1 year. Our findings question whether the diagnostic threshold for myocardial infarction should be based on the 99th centile derived from a normal reference population. FUNDING: The British Heart Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31923-8

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 388

Metadata

Authors
Shah, A. S. V., Anand, A., Strachan, F. E., Ferry, A. V., Lee, K. K., Chapman, A. R., Sandeman, D., Stables, C. L., Adamson, P. D., Andrews, J. P. M., Anwar, M. S., Hung, J., Moss, A. J., O'Brien, R., Berry, C., Findlay, I., Walker, S., Cruickshank, A., Reid, A., Gray, A., Collinson, P. O., Apple, F. S., McAllister, D. A., Maguire, D., Fox, K. A. A., Newby, D. E., Tuck, C., Harkess, R., Parker, R. A., Keerie, C., Weir, C. J., Mills, N. L., Marshall, L., Stewart, S. D., Fujisawa, T., Vallejos, C. A., Tsanas, A., Hautvast, M., McPherson, J., McKinlay, L., Malo, J., Fischbacher, C. M., Croal, B. L., Leslie, S. J., Walker, A., Wackett, T., Armstrong, R., Stirling, L., MacDonald, C., Sadat, I., Finlay, F., Charles, H., Linksted, P., Young, S., Alexander, B., & Duncan, C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-09
Volume
392
Issue
10151
Pages
919-928
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2889023120
Cited by
388
References
38
FWCI
28.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31923-8
The paper
Shah, A. S. V., Anand, A., Strachan, F. E., Ferry, A. V., Lee, K. K., Chapman, A. R., Sandeman, D., Stables, C. L., Adamson, P. D., Andrews, J. P. M., Anwar, M. S., Hung, J., Moss, A. J., O'Brien, R., Berry, C., Findlay, I., Walker, S., Cruickshank, A., Reid, A., . . . Duncan, C. (2018). High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31923-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.